Seek Returns

MEDP vs. SNY: Medpace vs. Sanofi Stock Comparison

How do Medpace (MEDP) and Sanofi (SNY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Medpace (MEDP) and Sanofi (SNY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but MEDP is classified in Life Sciences Tools & Services while SNY is classified in Pharmaceuticals.

Medpace (MEDP) trades as ordinary local shares, while Sanofi (SNY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for Medpace (MEDP) and Sanofi (SNY)
Profile ItemMEDPSNY
NameMedpace Holdings, Inc.Sanofi ADR
Country/RegionUnited StatesFrance
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesPharmaceuticals
GICS Sub-IndustryLife Sciences Tools & ServicesPharmaceuticals
Market Capitalization18.27 billion USD112.71 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateAugust 11, 2016July 1, 2002
Security TypeCommon StockADR

Price Performance

Cumulative Growth

MEDP
SNY
GSPC
Loading price history…
Medpace (MEDP) vs. Sanofi (SNY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Medpace (MEDP) and Sanofi (SNY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Medpace (MEDP) and Sanofi (SNY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Medpace (MEDP) and Sanofi (SNY)
MetricMEDPSNY
Total Return (1Y)13.29%2.73%
Total Return (3Y, Annualized)35.26%6.89%
Total Return (5Y, Annualized)24.49%3.16%

Risk Profile

Drawdown History

MEDP
SNY
GSPC
Loading price history…
Medpace (MEDP) vs. Sanofi (SNY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Medpace (MEDP) and Sanofi (SNY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Medpace (MEDP) and Sanofi (SNY)
MetricMEDPSNY
Volatility (1Y, Annualized)44.16%23.60%
Beta (5Y)1.100.28
Max Drawdown (5Y)-42.87%-33.52%
Avg. Volume (3M)258.39K3.29M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
MEDP and SNY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Medpace (MEDP) and Sanofi (SNY)
MetricMEDPSNY
Sharpe Ratio (1Y)0.20-0.07
Sortino Ratio (1Y)0.26-0.10

Profitability

ROE (TTM)

Medpace (MEDP) at 117.88% clears its industry range for ROE, a sharper capital-efficiency signal than Sanofi (SNY) at 5.72%, which is closer to a typical peer reading.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

117.88%

MEDP
117.88%
Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.72%

Max
109.18%
Q3
6.23%
SNY
5.72%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Medpace (MEDP) vs. Sanofi (SNY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Medpace (MEDP) at 18.24% keeps the most of each sales dollar — above its industry’s net margin range — and Sanofi (SNY) at 8.20% also retains a top-quartile share.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.24%

MEDP
18.24%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.20%

Max
18.05%
SNY
8.20%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Medpace (MEDP) vs. Sanofi (SNY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Medpace (MEDP) at 23.12% and Sanofi (SNY) at 30.89% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.12%

Max
83.12%
MEDP
23.12%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.89%

Max
83.12%
SNY
30.89%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Medpace (MEDP) vs. Sanofi (SNY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Medpace (MEDP) and Sanofi (SNY)
MetricMEDPSNY
ROE (TTM)117.88%5.72%
ROA (TTM)18.71%5.31%
Net Margin (TTM)18.24%8.20%
Operating Margin (TTM)23.12%30.89%
Gross Margin (TTM)72.24%73.68%

Growth

Revenue Growth

Both Medpace (MEDP) at 19.97% and Sanofi (SNY) at 5.49% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Medpace (MEDP) vs. Sanofi (SNY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Medpace (MEDP) at 20.98% and Sanofi (SNY) at 39.43% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Loading chart…
Medpace (MEDP) vs. Sanofi (SNY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Medpace (MEDP) and Sanofi (SNY)
MetricMEDPSNY
Revenue Growth (YoY)19.97%5.49%
Revenue Growth (3Y CAGR)20.12%4.82%
EPS Growth (YoY)20.98%39.43%
EPS Growth (3Y CAGR)28.04%6.02%

Financial Strength

Current Ratio (MRQ)

Both Medpace (MEDP) at 0.83 and Sanofi (SNY) at 1.12 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.83

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
MEDP
0.83
Min
0.10

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.12

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
SNY
1.12
Min
0.10
Loading chart…
Medpace (MEDP) vs. Sanofi (SNY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Medpace (MEDP) at 0.29 and Sanofi (SNY) at 0.27 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.29

Max
1.42
Q3
0.65
MEDP
0.29
Median
0.15
Q1
0.02
Min
0.00

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.27

Max
1.42
Q3
0.65
SNY
0.27
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Medpace (MEDP) vs. Sanofi (SNY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Medpace (MEDP) and Sanofi (SNY)
MetricMEDPSNY
Current Ratio (MRQ)0.831.12
Debt / Equity (MRQ)0.290.27
Net Debt / EBITDA-0.840.96

Dividends

Dividend Yield (TTM)

Neither Medpace (MEDP) nor Sanofi (SNY) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MEDP
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

SNY
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Medpace (MEDP) vs. Sanofi (SNY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Sanofi (SNY) reports payout ratio above 100% at 119.86%, meaning dividends exceeded current-period earnings; Medpace (MEDP) pays no dividend (payout 0.00%).

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MEDP
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

119.86%

SNY
119.86%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Medpace (MEDP) vs. Sanofi (SNY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Medpace (MEDP) and Sanofi (SNY)
MetricMEDPSNY
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%119.86%

Valuation

P/E Ratio (TTM)

Both Medpace (MEDP) at 36.26 and Sanofi (SNY) at 23.40 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.26

Max
85.34
Q3
43.46
MEDP
36.26
Median
26.69
Q1
13.30
Min
0.07

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.40

Max
85.34
Q3
43.46
Median
26.69
SNY
23.40
Q1
13.30
Min
0.07
Loading chart…
Medpace (MEDP) vs. Sanofi (SNY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

Sanofi (SNY) at 2.21 sits in the cheaper P/S ratio quartile while Medpace (MEDP) at 6.44 prices around its industry’s middle — SNY costs less per dollar of sales, though read it alongside growth and margins.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.44

Max
58.18
Q3
25.77
Median
7.30
MEDP
6.44
Q1
3.01
Min
0.01

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.21

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
SNY
2.21
Min
0.01
Loading chart…
Medpace (MEDP) vs. Sanofi (SNY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Sanofi (SNY) at 1.38 sits in the lower P/B ratio quartile relative to book while Medpace (MEDP) at 31.23 prices above its industry range — a wide valuation gap against assets.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.23

MEDP
31.23
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
SNY
1.38
Min
-5.59
Loading chart…
Medpace (MEDP) vs. Sanofi (SNY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Medpace (MEDP) and Sanofi (SNY)
MetricMEDPSNY
P/E Ratio (TTM)36.2623.40
P/S Ratio (TTM)6.442.21
P/B Ratio (MRQ)31.231.38
Free Cash Flow Yield (TTM)2.72%7.17%